Ketoprofen label warning on concurrent NSAID use supported by FDAer, cmte. members.
This article was originally published in The Tan Sheet
Executive Summary
KETOPROFEN LABEL WARNING AGAINST CONCURRENT NSAID USE was supported by FDA Topical Drug Products Deputy Director Linda Katz, MD, and some members of the agency's Nonprescription Drugs and Arthritis Advisory Committees at a July 14 meeting. During discussion of whether OTC ketoprofen labeling should bear a warning on the risk of taking more than one nonsteroidal anti-inflammatory drug at a time, Katz noted that the goal is "to make sure people understand that if they're taking ibuprofen, they don't want to take ketoprofen." FDA does not "want people taking multiple drugs for the same thing thinking that they're taking different classes of drugs," she added.